192 related articles for article (PubMed ID: 31177166)
1. Serum Prognostic Factors of Androgen-deprivation Therapy Among Japanese Men With
Kobayashi T; Namitome R; Hirata YU; Shiota M; Imada K; Kashiwagi E; Takeuchi A; Inokuchi J; Tatsugami K; Eto M
Anticancer Res; 2019 Jun; 39(6):3191-3195. PubMed ID: 31177166
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S
Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Significance of Time to Castration Resistance in Patients With Metastatic Castration-sensitive Prostate Cancer.
Miyake H; Matsushita Y; Watanabe H; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A
Anticancer Res; 2019 Mar; 39(3):1391-1396. PubMed ID: 30842173
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of time to prostate-specific antigen (PSA) nadir and its relationship to survival beyond time to PSA nadir for prostate cancer patients with bone metastases after primary androgen deprivation therapy.
Teoh JY; Tsu JH; Yuen SK; Chan SY; Chiu PK; Lee WM; Wong KW; Ho KL; Hou SS; Ng CF; Yiu MK
Ann Surg Oncol; 2015 Apr; 22(4):1385-91. PubMed ID: 25234025
[TBL] [Abstract][Full Text] [Related]
5. Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy.
Wang Y; Xu F; Pan J; Zhu Y; Shao X; Sha J; Wang Z; Cai Y; Liu Q; Dong B; Xue W; Huang Y
BMC Cancer; 2016 May; 16():329. PubMed ID: 27222030
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of J-CAPRA score for high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy.
Akakura K; Tsuji H; Suzuki H; Ichikawa T; Ishikawa H; Okada T; Kamada T; Harada M; Tsujii H; Shimazaki J
Jpn J Clin Oncol; 2014 Apr; 44(4):360-5. PubMed ID: 24585931
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of early changes in serum biomarker levels in patients with newly diagnosed metastatic prostate cancer.
Narita S; Nomura K; Hatakeyama S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Mitsuzuka K; Tochigi T; Tsuchiya N; Ohyama C; Arai Y; Nagashima K; Habuchi T
Sci Rep; 2019 Aug; 9(1):12071. PubMed ID: 31427687
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of Lactate Dehydrogenase in Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Mori K; Kimura S; Parizi MK; Enikeev DV; Glybochko PV; Seebacher V; Fajkovic H; Mostafaei H; Lysenko I; Janisch F; Egawa S; Shariat SF
Clin Genitourin Cancer; 2019 Dec; 17(6):409-418. PubMed ID: 31558410
[TBL] [Abstract][Full Text] [Related]
9. Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients.
Shiota M; Terada N; Saito T; Yokomizo A; Kohei N; Goto T; Kawamura S; Hashimoto Y; Takahashi A; Kimura T; Tabata KI; Tomida R; Hashimoto K; Sakurai T; Shimazui T; Sakamoto S; Kamiyama M; Tanaka N; Mitsuzuka K; Kato T; Narita S; Yasumoto H; Teraoka S; Kato M; Osawa T; Nagumo Y; Matsumoto H; Enokida H; Sugiyama T; Kuroiwa K; Inoue T; Mizowaki T; Kamoto T; Kojima T; Kitamura H; Sugimoto M; Nishiyama H; Eto M;
Cancer Sci; 2021 Apr; 112(4):1524-1533. PubMed ID: 33159829
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment plasma fibrinogen as an independent prognostic indicator of prostate cancer patients treated with androgen deprivation therapy.
Wang Y; Yin W; Wang Z; Huang J; Pan J; Zhu Y; Xu F; Shao X; Sha J; Cai Y; Liu Q; Dong B; Xue W; Huang Y
Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):209-15. PubMed ID: 26951714
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes and nadir prostate-specific antigen (PSA) according to initial PSA levels in primary androgen deprivation therapy for metastatic prostate cancer.
Kitagawa Y; Ueno S; Izumi K; Kadono Y; Mizokami A; Hinotsu S; Akaza H; Namiki M
World J Urol; 2016 Mar; 34(3):319-27. PubMed ID: 26089252
[TBL] [Abstract][Full Text] [Related]
12. Prognostic model with alkaline phosphatase, lactate dehydrogenase and presence of Gleason pattern 5 for worse overall survival in low-risk metastatic hormone-sensitive prostate cancer.
Tsuzuki S; Kawano S; Fukuokaya W; Mori K; Nishikawa H; Tashiro K; Watanabe D; Uchimoto T; Nishimura K; Yano Y; Murakami M; Koike Y; Hata K; Koide H; Miki J; Abe H; Yamada H; Naruoka T; Sugaya S; Kimura T; Tomita M; Nakajo H; Egawa S
Jpn J Clin Oncol; 2021 Nov; 51(11):1665-1671. PubMed ID: 34296282
[TBL] [Abstract][Full Text] [Related]
13. Novel metastatic burden-stratified risk model in de novo metastatic hormone-sensitive prostate cancer.
Shiota M; Terada N; Kitamura H; Kojima T; Saito T; Yokomizo A; Kohei N; Goto T; Kawamura S; Hashimoto Y; Takahashi A; Kimura T; Tabata KI; Tomida R; Hashimoto K; Sakurai T; Shimazui T; Sakamoto S; Kamiyama M; Tanaka N; Mitsuzuka K; Kato T; Narita S; Yasumoto H; Teraoka S; Kato M; Osawa T; Nagumo Y; Matsumoto H; Enokida H; Sugiyama T; Kuroiwa K; Inoue T; Sugimoto M; Mizowaki T; Kamoto T; Nishiyama H; Eto M;
Cancer Sci; 2021 Sep; 112(9):3616-3626. PubMed ID: 34145921
[TBL] [Abstract][Full Text] [Related]
14. Lactate Dehydrogenase Is a Serum Prognostic Factor in Clinically Regional Lymph Node-positive Prostate Cancer.
Blas L; Shiota M; Yamada S; Ieiri K; Nagakawa S; Tsukahara S; Matsumoto T; Kashiwagi E; Takeuchi A; Inokuchi J; Shiga KI; Yokomizo A; Eto M
Anticancer Res; 2021 Aug; 41(8):3885-3889. PubMed ID: 34281850
[TBL] [Abstract][Full Text] [Related]
15. Genetic Polymorphism in Sex Hormone-binding Globulin With a Prognosis of Androgen Deprivation Therapy in Metastatic Prostate Cancer Among Japanese Men.
Shiota M; Fujimoto N; Tsukahara S; Ushijima M; Takeuchi A; Kashiwagi E; Inokuchi J; Tatsugami K; Uchiumi T; Eto M
Clin Genitourin Cancer; 2019 Jun; 17(3):e387-e393. PubMed ID: 31036465
[TBL] [Abstract][Full Text] [Related]
16. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
Xie W; Nakabayashi M; Regan MM; Oh WK
Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
[TBL] [Abstract][Full Text] [Related]
17. A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy.
Lv W; Shang H; Pei X; Chen Y; Xie H; He D; Wang X; Li L
Int Urol Nephrol; 2017 Jan; 49(1):61-67. PubMed ID: 27837416
[TBL] [Abstract][Full Text] [Related]
18. Impact of early changes in serum biomarkers following androgen deprivation therapy on clinical outcomes in metastatic hormone-sensitive prostate cancer.
Sato H; Narita S; Tsuchiya N; Koizumi A; Nara T; Kanda S; Numakura K; Tsuruta H; Maeno A; Saito M; Inoue T; Satoh S; Nomura K; Habuchi T
BMC Urol; 2018 May; 18(1):32. PubMed ID: 29739368
[TBL] [Abstract][Full Text] [Related]
19. Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy.
Ravi P; Karnes RJ; Rangel LJ; Pagliaro LC
J Urol; 2018 Nov; 200(5):1075-1081. PubMed ID: 29709664
[TBL] [Abstract][Full Text] [Related]
20. Testosterone Reduction of ≥ 480 ng/dL Predicts Favorable Prognosis of Japanese Men With Advanced Prostate Cancer Treated With Androgen-Deprivation Therapy.
Yamamoto S; Sakamoto S; Minhui X; Tamura T; Otsuka K; Sato K; Maimaiti M; Kamada S; Takei A; Fuse M; Kawamura K; Imamoto T; Komiya A; Akakura K; Ichikawa T
Clin Genitourin Cancer; 2017 Dec; 15(6):e1107-e1115. PubMed ID: 28882738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
